DVYSR Share Price Performance
SEK 0
-118.50 (-100.00%)
Price SEK 0
Fair ValueSEK 156.12
Share Pricen/a
Devyser Diagnostics AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
DVYSR Community Narratives
AN
Fair Value SEK 156.12 29.8% undervalued intrinsic discount
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
Catalysts About Devyser Diagnostics Devyser Diagnostics develops and commercializes specialized genetic testing solutions for transplantation and hereditary diseases, with a growing footprint in regulated clinical markets. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 156.12
29.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
35.52% p.a.
Profit Margin
28.99%
Future PE
17.59x
Price in 2028
SEK 181.67
Trending Discussion
Recently Updated Narratives
AN
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
Fair Value: SEK 156.12 29.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Devyser Diagnostics AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 12, 2026
- -1.51
- 81.95%
- -10.38%
- 0.1%
About DVYSR
- Founded
- 2004
- Employees
- 108
- CEO
- WebsiteView website
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.
